Arca
Skip to content

Gastrointestinal cancer

Drug research and approvals for gastrointestinal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 3,495 studies of gastrointestinal cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 10 drug trials for it since 2013.

  • Recruiting worldwide: 3,495
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 3,495 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Feb 19, 2025A phase 2 nonrandomized, open-label, multisite study to evaluate the safety and efficacy of raludotatug deruxtecan in participants with gastrointestinal cancersRALUDOTATUG DERUXTECAN (R-DXD (MK-5909)Merck & Co. (MSD)Ongoing
Sep 26, 2024A phase 1/2 study to evaluate the safety and efficacy of patritumab deruxtecan in gastrointestinal cancersPATRITUMAB (MK-1022, U3-1402)Merck & Co. (MSD)Ongoing
May 23, 2024A phase 1/2 study to evaluate the safety and efficacy of mk-2870 monotherapy or in combination with other anticancer agents in gastrointestinal cancersMK-2870 (SACITUZUMAB TIRUMOTECAN) / 5-FLUOROURACIL (5-FU) / CALCIUM FOLINATEMerck & Co. (MSD)Ongoing
Mar 26, 2024A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 193 in combination with other therapies in subjects with advanced…AMG 193AmgenPending
Dec 22, 2022A phase Ia/ib, open label, multicentre, dose escalation study of bi 905711 in combination with chemotherapy followed by expansion cohorts in patients with…BI 905711BOEHRINGER INGELHEIM (CANADA) LTD LTEEPending
Feb 9, 2022A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous…ABELACIMABANTHOS THERAPEUTICS, INC.Closed
Apr 25, 2019A phase 3 randomized placebo-controlled double-blind study of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in patients receiving…NPLATEAmgenOngoing
Mar 13, 2019Phase Ib study of gevokizumab in combination with standard of care anticancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer…GEVOKIZUMAB (VPM087) / PACLITAXELNovartis Pharmaceuticals CorporationClosed
Jun 2, 2014An open-labeled, multicenter phase II study of cabazitaxel in refractory metastatic gastric or gastroesophageal adenocarcinomaCABAZITAXELDR YOO-JOUNG KOPending
Oct 18, 2013A phase Ib clinical study of bbi608 in combination with standard chemotherapies in adult patients with advanced gastrointestinal cancerNAPABUCASIN (BBI608)/ BEVACIZUMABSUMITOMO DAINIPPON PHARMA ONCOLOGY INCClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.